WuXi Biologics, Harbour BioMed in Strategic Mfg. Alliance

WuXi Biologics and Harbour BioMed have entered a strategic collaboration for the development and manufacture of Harbour’s lead HCAb antibody. WuXi Biologics will support the supply of Harbour’s products for clinical trials under Investigational New Drug (IND) applications in China and worldwide.
 
“In about a year’s time, our scientists have moved our leading HCAb molecule into IND enabling stage. We are excited to collaborate with WuXi Biologics to accelerate further development of this molecule. This collaboration is aligned with our strategy to partner with industry leaders to bring forward innovative therapeutics that will help patients,” said Dr. Jingsong Wang, chief executive officer of Harbour BioMed.
 
“Harbour’s trust in WuXi Biologics to develop this novel format of HCAb is a strong testament of WuXi Biologics as a global leader in technology,” said Dr. Chris Chen, chief executive officer of WuXi Biologics, “We have enabled more than 20 complex molecules to the clinic including different bispecific formats, ADCs, fusion proteins and novel protein scaffolds. We aim to empower anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing.”